Archive for the ‘spain’ Category
Last author José G. Castaño told us the manipulation occurred at the Universidad Autónoma de Madrid, where he and one other co-author are based. He declined to name who was responsible.
Here’s the retraction notice for “Cytomegalovirus promoter up-regulation is the major cause of increased protein levels of unstable reporter proteins after treatment of living cells with proteasome inhibitors:”
With retraction notices continuing to pour in, we like to occasionally take the opportunity to cover several at a time to keep up.
We’ve compiled a handful of retractions that were all issued to papers that were published twice by at least one of the same authors — known as duplication. (Sometimes, this can be the publisher’s fault, although that doesn’t appear to be the case in any of the following examples.)
So here are five recently retracted papers that were pulled because of duplication: Read the rest of this entry »
In June 2015, we reported that the publisher was investigating anonymous allegations of more than a dozen instances of manipulation of images in the papers published in Cell and Molecular Cell in 1999 and 2001, respectively.
After assessing the original high-resolution versions of images from the laboratory notebook of Maria Pia Cosma, the first author of both papers, the journals have not found enough evidence to determine that fraud had occurred.
The paper — about an “extremely rare” instance where a fetus was diagnosed with both a form of dwarfism and a chromosomal condition known as Klinefelter syndrome — was retracted from Case Reports in Obstetrics and Gynecology (CROG).
The first author of the paper told us the report was the result of a “big misunderstanding” between her and a former colleague, and she alerted the journal as soon as she noticed the case had already been reported in BMC Pediatrics.
According to the authors’ institution, IMIM in Barcelona, all co-authors are aware of the retraction. The penultimate author — Antonio García de Herreros — retracted three papers in May from the Journal of Biological Chemistry for reusing images to represent different experiments, and recently corrected multiple figures in a Journal of Cell Science paper over “possible duplications and/or splices.”
Biologists are retracting three papers after the journal concluded they contain reused images, designed to represent different experiments. The authors stand by the conclusions, some of which they say have been “extensively validated.”
The Journal of Biological Chemistry used image analysis software to evaluate the images, first published at least a decade ago. Unfortunately, the raw data behind the problematic images were not available. The authors have also corrected a fourth paper in another journal, and wrote on PubPeer that they are working with journals to address concerns in three more.
The papers share two authors: Mireia Duñach at the Autonomous University of Barcelona, and Antonio García de Herreros at the Institut Hospital del Mar d’Investigacions Mèdiques. A representative of the Institut Hospital del Mar d’Investigacions Mèdiques told us it is looking into Garcia de Herreros’s work.
We’ll start with “β-Catenin N- and C-terminal tails modulate the coordinated binding of adherens junction proteins to β-catenin,” which has been cited 45 times since it was published in 2002, according to Thomson Reuters Web of Science. The retraction notice says:
The Journal of Sex & Marital Therapy has retracted a 2012 paper by a pair of authors in Spain who failed to obtain approval to adapt the model of sexual function they used in their study.
The article indicates that the work was based on previous research. But that declaration wasn’t enough to satisfy the creators of the model involved.
The 2003 paper, “The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors,” has been cited 566 times, according to Thomson Reuters Web of Science. One of the authors is the last author on a recent high profile retraction from Nature Genetics, which cost the first author a grant from the European Molecular Biology Organisation.
We don’t know what exactly the internal investigation into Susana González’s work found; El Pais relied on anonymous sources, and the CNIC confirmed only that they dismissed her on February 29th. There are allegations against her work on PubPeer, but we don’t know what role those played in the investigation.
(We had the story translated; here’s a PDF of the article in English.)
González denies that she committed misconduct, the paper reports:
Earlier this year, authors retracted a meeting abstract about a diabetes drug, following the revelation that the biotech that funded the trial committed misconduct.
The retraction was initiated by corresponding author Itamar Raz, at Hadassah Medical Center in Israel. The journal didn’t receive a response from any co-authors who were affiliated with the biotech company, Andromeda, so they were not included in the retraction process.
A few months after Hyperion Therapeutics acquired Andromeda’s diabetes drug DiaPep277, Hyperion announced it had evidence that some employees of Andromeda had “engaged in serious misconduct,” such as using un-blinded data and manipulating the analyses. Two relevant studies on the drug, designed to block the immune response that leads to type 1 diabetes, were retracted last year.
Here’s the retraction note for the abstract “Abstracts of the 50th Annual Meeting of the EASD, Vienna 2014. ‘Evaluation of DiaPep277® treatment in type 1 diabetes by integrated analysis,’” published in the May issue of the journal: